Philip E. Bourne

You Wu, Philip E. Bourne, Lei Xie

Artificial intelligence (AI) has sparked immense interest in drug discovery, but most current approaches only digitize existing high-throughput experiments. They remain constrained by conventional pipelines. As a result, they do not address the fundamental challenges of predicting drug effects in humans. Similarly, biomedical digital twins, largely grounded in real-world data and mechanistic models, are tailored for late-phase drug development and lack the resolution to model molecular interactions or their systemic consequences, limiting their impact in early-stage discovery. This disconnect between early discovery and late development is one of the main drivers of high failure rates in drug discovery. The true promise of AI lies not in augmenting current experiments but in enabling virtual experiments that are impossible in the real world: testing novel compounds directly in silico in the human body. Recent advances in AI, high-throughput perturbation assays, and single-cell and spatial omics across species now make it possible to construct programmable virtual humans: dynamic, multiscale models that simulate drug actions from molecular to phenotypic levels. By bridging the translational gap, programmable virtual humans offer a transformative path to optimize therapeutic efficacy and safety earlier than ever before. This perspective introduces the concept of programmable virtual humans, explores their roles in a new paradigm of drug discovery centered on human physiology, and outlines key opportunities, challenges, and roadmaps for their realization.

Tian Cai, Li Xie, Muge Chen et al.

Advances in biomedicine are largely fueled by exploring uncharted territories of human biology. Machine learning can both enable and accelerate discovery, but faces a fundamental hurdle when applied to unseen data with distributions that differ from previously observed ones -- a common dilemma in scientific inquiry. We have developed a new deep learning framework, called {\textit{Portal Learning}}, to explore dark chemical and biological space. Three key, novel components of our approach include: (i) end-to-end, step-wise transfer learning, in recognition of biology's sequence-structure-function paradigm, (ii) out-of-cluster meta-learning, and (iii) stress model selection. Portal Learning provides a practical solution to the out-of-distribution (OOD) problem in statistical machine learning. Here, we have implemented Portal Learning to predict chemical-protein interactions on a genome-wide scale. Systematic studies demonstrate that Portal Learning can effectively assign ligands to unexplored gene families (unknown functions), versus existing state-of-the-art methods, thereby allowing us to target previously "undruggable" proteins and design novel polypharmacological agents for disrupting interactions between SARS-CoV-2 and human proteins. Portal Learning is general-purpose and can be further applied to other areas of scientific inquiry.

Sean Mullane, Ruoyan Chen, Sri Vaishnavi Vemulapalli et al.

The biological function of a protein stems from its 3-dimensional structure, which is thermodynamically determined by the energetics of interatomic forces between its amino acid building blocks (the order of amino acids, known as the sequence, defines a protein). Given the costs (time, money, human resources) of determining protein structures via experimental means such as X-ray crystallography, can we better describe and compare protein 3D structures in a robust and efficient manner, so as to gain meaningful biological insights? We begin by considering a relatively simple problem, limiting ourselves to just protein secondary structural elements. Historically, many computational methods have been devised to classify amino acid residues in a protein chain into one of several discrete secondary structures, of which the most well-characterized are the geometrically regular $α$-helix and $β$-sheet; irregular structural patterns, such as 'turns' and 'loops', are less understood. Here, we present a study of Deep Learning techniques to classify the loop-like end cap structures which delimit $α$-helices. Previous work used highly empirical and heuristic methods to manually classify helix capping motifs. Instead, we use structural data directly--including (i) backbone torsion angles computed from 3D structures, (ii) macromolecular feature sets (e.g., physicochemical properties), and (iii) helix cap classification data (from CAPS-DB)--as the ground truth to train a bidirectional long short-term memory (BiLSTM) model to classify helix cap residues. We tried different network architectures and scanned hyperparameters in order to train and assess several models; we also trained a Support Vector Classifier (SVC) to use as a baseline. Ultimately, we achieved 85% class-balanced accuracy with a deep BiLSTM model.